Home
Why EFUDEX®?
Indications
How EFUDEX® Works
Treatment
FAQ / What to Expect
Other Products
Links
References
For Additional Information Call:
United States 1.800.556.1937


What Can I Expect During My AK Treatment?

During the first 2 to 4 weeks of treatment, the areas of your skin affected by AK or sBCC lesions will probably turn red and look and feel irritated. This is typical and should not cause concern. The redness, crusting, and peeling are signs that EFUDEX® is working to eliminate the unhealthy cells. Even though this stage of treatment may be unattractive and somewhat uncomfortable, it is important that you do not stop the therapy.

Some patients may be concerned with the inflammation associated with EFUDEX® therapy. Talk to your doctor; he or she can best assess the situation and advise you.

Areas of your skin where there were no lesions may become red and inflamed. This is because abnormal cells can become inflamed even if the cells were not previously noticeable on the skin's surface.1, 18-20 The more AKs you have, the more redness and inflammation you can expect during treatment.

"Photographs reproduced courtesy of the Skin Cancer Foundation, New York, NY. For more information about skin cancer prevention, detection and treatment,visit their website at www.skincancer.org"
What Can I Expect During My sBCC Treatment?

Your sBCC treatment lasts for at least 3-6 weeks, and up to 10-12 weeks. Your area of treatment may experience mild pain.21

Printer Friendly
Prescribing Information
  • Over 14 million prescriptions have been written for Efudex over last 30 years5
  • High success rates
IMPORTANT SAFETY INFORMATION
EFUDEX® (fluorouracil) Topical Solutions and Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.
EFUDEX is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant.
The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, scaling, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration.
Please see complete Prescribing Information for EFUDEX.
© Valeant Pharmaceuticals International 2005  Legal and Privacy Statement
Efudex® is a registered trademark of Valeant Pharmaceuticals International